본문 바로가기

기술동향

홈 > BT정보 > 기술동향

scrap print facebook twitter me2day
글 읽기

The Year in Biotech

분류 기술동향 > 종합
출처 http://www.technologyreview.com 조회 2514
자료발간일 2007-12-28 등록일 2007-12-31
내용바로가기 http://www.technologyreview.com/Biotech/19982/
평점 평점이 없습니다.

The Year in Biotech

 

 

Genomics Gets Really Personal
This year may be remembered as the turning point for personal genomics, when broad gene testing for individuals finally came within reach. Two genomic pioneers–James Watson, codiscover of the structure of DNA, and Craig Venter, leader of the private effort to sequence the genome–published the sequence of their own genomes, revealing personal disease risks. (See “The $2 Million Genome” and “Craig Venter’s Genome.”)

 

Taking advantage of the explosion in human genomics data, several companies launched direct-to-consumer gene-testing services that analyze an individual’s genetic risk of contacting a range of diseases, including Alzheimer’s, diabetes, and cancer. (See “Your Future, on a Chip” and “Your Personal Genome.”) Critics say it’s not yet clear how useful such tests will be in preventing disease. So with price tags ranging from about $1,000, for a microarray analysis that analyzes a million genetic variations, to $350,000, for a full genome sequence, it might be worth waiting.

관련기사
Colorado Looks to Grow Biotech Industry 2017-07-19
Green Light for CAR-T Leukemia Treatment Is an Historic Moment for Biotechnology 2017-07-19
Arix leads $45M series B for gene therapy biotech LogicBio 2017-06-29
Biotech s as the bones of Trump's plans on pricing emerge 2017-06-23
Early biotech financing healthy, but R&D productivity needs to look left field 2017-06-20
Korean biotech Orum raises $8M for cell-penetrating antibody tech 2017-06-15
Shock U.K. election result creates uncertainty for biotech 2017-06-13
Swiss biotech NLS touts positive ADHD data, plots late-stage tests 2017-06-01
60 Biotech and Biopharma Recruiters 2017-05-02
Biotech Engages Patients Earlier than Ever 2017-03-14